Objective  To explore the influence of combination of recombinant human collagen dressing and promestriene ointment on symptoms and vaginal microecology in patients with atrophic vaginitis.

Methods  The data of patients with atrophic vaginitis admitted to the General Hospital of the People's Liberation Army were retrospectively collected from April 2017 to April 2024. According to treatment methods, the enrolled patients were divided into a study group (recombinant human collagen dressing combined with promestriene ointment for 7 days) and a control group (promestriene ointment for 7 days). The efficacy, symptom disappearance time, vaginal microecology and adverse reactions were compared between groups, and recurrence rate of atrophic vaginitis within 1 month was observed.

Results  A total of 150 patients were screened and included, 77 in the study group and 73 in the control group. After treatment, the total therapeutic efficacy in the study group was higher than that in the control group (89.61% vs. 76.71%, P<0.05). The disappearance durations of abnormal leucorrhea, vulva pruritus and vulva burning pain in the study group were significantly shorter compared with those in the control group (all P<0.05). The vaginal pH value in the study group was lower, while the positive rate of Lactobacillus and proportions of vaginal flora density grade II-III and diversity grade II-III were higher compared to the control group (all P<0.05). During treatment, no significant difference was exhibited in the total incidence rate of adverse reactions between the two groups (P>0.05). The recurrence rate was lower in the study group than that in the control group within 1 month of follow-up (P<0.05).

Conclusion  Recombinant human collagen dressing combined with promestriene ointment is more effective than promestriene ointment alone in improving the efficacy of patients with atrophic vaginitis, and can better shorten the disappearance durations of symptoms such as abnormal leucorrhea, vulva pruritus and vulva burning pain, correct the disorder of vaginal microecology, and reduce the short-term recurrence rate of vaginitis, and offer good safety.

1.Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review[J]. Int Urogynecol J, 2015, 26(1): 15-28. DOI: 10.1007/s00192-014-2464-0.

2.Sarmento ACA, Costa APF, Lírio J, et al. Efficacy of hormonal and nonhormonal approaches to vaginal atrophy and sexual dysfunctions in postmenopausal women: a systematic review[J]. Rev Bras Ginecol Obstet, 2022, 44(10): 986-994. DOI: 10.1055/s-0042-1756148.

3.Zeng H, Li H, Wang L, et al. Recombinant humanized type III collagen inhibits ovarian cancer and induces protective anti-tumor immunity by regulating autophagy through GSTP1[J]. Mater Today Bio, 2024, 28: 101220. DOI: 10.1016/j.mtbio.2024.101220.

4.Zhang Y, Li Y, Wu X, et al. Recombinant humanized collagen: a promising treatment for pelvic organ prolapse via enhanced fibroblast function and angiogenesis[J]. Int Urogynecol J, 2025, 36(4): 881-893. DOI: 10.1007/s00192-025-06117-x.

5.Ye S, Chen B, Jeevithan L, et al. Recombinant humanized collagen enhances secreted protein levels of fibroblasts and facilitates rats' skin basement membrane reinforcement[J]. J Funct Biomater, 2025, 16(2): 47. DOI: 10.3390/jfb16020047.

6.陈梦捷, 张三元, 徐迎亚, 等. 重组Ⅲ型人源化胶原蛋白冻干纤维治疗阴道松弛症随机对照临床试验研究[J]. 中国实用妇科与产科杂志, 2024, 40(6): 665-668. [Chen MJ, Zhang SY, Xu YY, et al. Randomized controlled clinical trial of recombinant humanized type Ⅲ collagen freeze-dried fibers for the treatment of vaginal laxity[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2024, 40(6): 665-668.] DOI: 10.19538/j.fk2024060119.

7.中华医学会, 编著. 临床诊疗指南·妇产科学分册[M]. 北京: 人民卫生出版社, 2007: 23-25.

8.莫瑶华, 徐方艳, 沈兰, 等. 苦参凝胶联合普罗雌烯阴道胶丸与乳杆菌活菌胶囊治疗老年萎缩性阴道炎有效性及安全性研究[J]. 中国实用妇科与产科杂志, 2023, 39(7): 753-756. [Mo YH, Xu FY, Shen L, et al. Efficacy and safety of Sophora Flavescens gel combined with prolestrene vaginal capsules and Lactobacillus vaginal capsules in the treatment of senile atrophic vaginitis[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2023, 39(7): 753-756.] DOI: 10.19538/j.fk2023070117.

9.中华医学会妇产科学分会感染性疾病协作组. 阴道微生态评价的临床应用专家共识[J]. 中华妇产科杂志, 2016, 51(10): 721-723. [Infectious Diseases Cooperative Group of Obstetrics and Gynecology Branch of Chinese Medical Association. Expert consensus on the clinical application of vaginal microecology evaluation[J]. Chinese Journal of Obstetrics and Gynecology, 2016, 51(10): 721-723.] DOI: 10.3760/cma.j.issn.0529-567x.2016.10.001.

10.Hao Y, Zhao B, Wu D, et al. Recombinant humanized collagen type XVII promotes oral ulcer healing via anti-inflammation and accelerate tissue healing[J]. J Inflamm Res, 2024, 17: 4993-5004. DOI: 10.2147/JIR.S470649.

11.Wang J, Qiu H, Xu Y, et al. The biological effect of recombinant humanized collagen on damaged skin induced by UV-photoaging: an in vivo study[J]. Bioact Mater, 2021, 11: 154-165. DOI: 10.1016/j.bioactmat.2021.10.004.

12.薛海玉. 替硝唑阴道泡腾片联合普罗雌烯阴道胶丸治疗萎缩性阴道炎患者的临床疗效[J]. 中国药物与临床, 2020, 20(8): 1365-1367. [Xue HY. Clinical efficacy of tinidazole vaginal effervescent tablets combined with proestradiol vaginal gelatin capsules in treating senile vaginitis[J]. Chinese Remedies & Clinics, 2020, 20(8): 1365-1367.] DOI: 10.11655/zgywylc2020.08.062.

13.Benini V, Ruffolo AF, Casiraghi A, et al. New innovations for the treatment of vulvovaginal atrophy: an up-to-date review[J]. Medicina (Kaunas), 2022, 58(6): 770. DOI: 10.3390/medicina58060770.

14.You S, Liu S, Dong X, et al. Intravaginal administration of human type III collagen-derived biomaterial with high cell-adhesion activity to treat vaginal atrophy in rats[J]. ACS Biomater Sci Eng, 2020, 6(4): 1977-1988. DOI: 10.1021/acsbiomaterials.9b01649.

15.吕广伟, 吕腾, 于新平, 等. 重组人源胶原蛋白局部应用对绝经后阴道壁组织病理学的影响[J]. 山东医药, 2022, 62(7): 61-63. [Lyu GW, Lyu T, Yu XP, et al. Effects of local application of recombinant human collagen on histopathology of postmenopausal vaginal wall tissue[J]. Shandong Medical Journal, 2022, 62(7): 61-63.] DOI: 10.3969/j.issn.1002-266X.2022.07.016.

16.You S, Zhu Y, Li H, et al. Recombinant humanized collagen remodels endometrial immune microenvironment of chronic endometritis through macrophage immunomodulation[J]. Regen Biomater, 2023, 10: rbad033. DOI: 10.1093/RB/RBAD033.

17.Wang L, Zeng H, Li H, et al. Recombinant humanized type I collagen remodels decidual immune microenvironment at maternal-fetal interface by modulating Th17/Treg imbalance[J]. Int J Biol Macromol, 2024, 276(Pt 2): 133994. DOI: 10.1016/j.ijbiomac.2024.133994.

18.Mitchell CM, Ma N, Mitchell AJ, et al. Association between postmenopausal vulvovaginal discomfort, vaginal microbiota, and mucosal inflammation[J]. Am J Obstet Gynecol, 2021, 225(2): 159. e1-159. e15. DOI: 10.1016/j.ajog.2021.02.034.

19.Saraf VS, Sheikh SA, Ahmad A, et al. Vaginal microbiome: normalcy vs dysbiosis[J]. Arch Microbiol, 2021, 203(7): 3793-3802. DOI: 10.1007/s00203-021-02414-3.

20.李琴娣, 陈红霞, 徐展翅. 甲硝唑联合雌二醇凝胶对老年混合性阴道炎患者阴道微生态和机体免疫的影响[J]. 中国性科学, 2023, 32(10): 110-113. [Li QD, Chen HX, Xu ZC. Effects of metronidazole combined with estradiol gel on vaginal microecology and immunity in elderly patients with mixed vaginitis[J]. Chinese Journal of Human Sexuality, 2023, 32(10): 110-113.] DOI: 10.3969/j.issn.1672-1993.2023.10.028.

21.张智虹, 王星. 雌激素局部与全身序贯应用治疗萎缩性阴道炎的临床观察[J]. 中国临床医生杂志, 2020, 48(2): 216-220. [Zhang ZH, Wang X. Clinical observation of local and systemic sequential application of estrogen in the treatment of senile vaginitis[J]. Chinese Journal for Clinicians, 2020, 48(2): 216-220.] DOI: 10.3969/j.issn.2095-8552.2020.02.030.